trending Market Intelligence /marketintelligence/en/news-insights/trending/o7kgjfalx1t-evefmnkkbw2 content esgSubNav
In This List

IntelGenx acquires pharmaceutical consulting firm for C$5M

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


IntelGenx acquires pharmaceutical consulting firm for C$5M

IntelGenx Technologies Corp. said it was acquiring a Montreal, Quebec-based pharmaceutical consulting firm for C$5 million in cash.

The Canadian pharmaceutical company intends to fund the acquisition of Laboval Inc. via a private placement to raise at least US$10 million.

The C$5 million acquisition amount is subject to Laboval achieving certain revenue milestones over two years after the deal is closed.

IntelGenX President and CEO Horst Zerbe said the deal will help reduce the company's overall cost structure by bringing quality control testing in-house.